ERBB2 and non-small cell lung carcinoma: A large phase II trial including 60 patients with refractory NSCLC with HER2 mutations revealed an ORR of 30%, with a median Duration of Response (DoR) of 6.9 months and a median PFS and OS of 6.9 and 14.4 months, respectively [70].